Use of standard markers and incorporation of molecular markers into breast cancer therapy

Cancer

Volumn 117, Issue 8, 2011, Pages 1575-1582

  Kaufmann, Manfred ^a   Pusztai, Lajos ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MOLECULAR MARKER; PROGESTERONE RECEPTOR;

BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER RESEARCH; CANCER THERAPY; CLINICAL DECISION MAKING; CONSENSUS DEVELOPMENT; GENOMICS; HIGH RISK PATIENT; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION PROFILING; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79953797516     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25660     Document Type: Review

References (46)

1. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25: 5287-5312. (Pubitemid 350232263)
2. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ,; panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009; 20: 1319-1329.
3. Sotiriou C, Pusztai L., Gene-expression signatures in breast cancer. N Engl J Med. 2009; 360: 790-800.
4. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415: 530-536. (Pubitemid 34130608)
5. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347: 1999-2009. (Pubitemid 35461656)
6. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351: 2817-2826. (Pubitemid 40051905)
7. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006; 98: 262-272. (Pubitemid 43264710)
8. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98: 10869-10874. (Pubitemid 32878711)
9. Ahr A, Karn T, Solbach C, et al. Identification of high risk breast-cancer patients by gene expression profiling. Lancet. 2002; 359: 131-132. (Pubitemid 34112543)
10. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005; 365: 671-679. (Pubitemid 40260888)
11. Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A. 2005; 102: 3738-3743. (Pubitemid 40354681)
12. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006; 24: 4236-4244. (Pubitemid 46630780)
13. Ma XJ, Hilsenbeck SG, Wang W, et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006; 24: 4611-4619. (Pubitemid 46630959)
14. Bonnefoi H, Potti A, Delorenzi M, et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol. 2007; 8: 1071-1078. (Pubitemid 350182953)
15. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27: 1160-1167.
16. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005; 11: 5678-5685. (Pubitemid 41170290)
17. Rody A, Karn T, Solbach C, et al. The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast. 2007; 16: 235-240. (Pubitemid 46796861)
18. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006; 355: 560-569. (Pubitemid 44200649)
19. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 2007; 25: 1239-1246. (Pubitemid 46640570)
20. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008; 10: R65.
21. Reyal F, van Vliet MH, Armstrong NJ, et al. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res. 2008; 10: R93.
22. Karn T, Metzler D, Ruckhaberle E, et al. Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer. Breast Cancer Res Treat. 2010; 120: 567-579.
23. Sparano JA, Goldstein LJ, Childs BH, et al. Relationship between topoisomerase 2A RNA expression and recurrence after adjuvant chemotherapy for breast cancer. Clin Cancer Res. 2009; 15: 7693-7700.
24. Rody A, Karn T, Ruckhaberle E, et al. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast Cancer Res Treat. 2009; 113: 457-466.
25. Mager SR, Oomen MH, Morente MM, et al. Standard operating procedure for the collection of fresh frozen tissue samples. Eur J Cancer. 2007; 43: 828-834. (Pubitemid 46389483)
26. NCI Best Practices for Biospecimen Resources. 2007. Available at
27. Leyland-Jones, Ambrosone CB, Bartlett J, et al. Recommendations for collection and handling of specimens from group breast cancer clinical trials. J Clin Oncol. 2008; 26: 5638-5644.
28. Marchionni L, Wilson RF, Wolff AC, et al. Systematic review: gene expression profiling assays in early-stage breast cancer. Ann Intern Med. 2008; 148: 358-369. (Pubitemid 351665467)
29. Bueno-de-Mesquita JM, van Harten WH, Retel VP, et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol. 2007; 8: 1079-1087. (Pubitemid 350182954)
30. Goldstein LJ, Gray R, Badve S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008; 26: 4063-4071.
31. Liang H, Brufsky AM, Lembersky BB, Rastogi P, Vogel VG., A retrospective analysis of the impact of oncotype DX low recurrence score results on treatment decisions in a single academic breast cancer center. Breast Cancer Res Treat. 2007; 106: S105. Abstract 2061.
32. Kelly CM, Krishnamurthy S, Bianchini G, et al. Utility of Oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer. 2010 (Epub ahead of print).
33. Cuzick J, Dowsett M, Wale C, et al. Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrence scoreâresults from TransATAC. Cancer Res. 2009; 69 (Suppl). Abstract 74.
34. Viale G, Regan MM, Dell'Orto P, et al. Central review of ER, PgR and HER2 in BIG 1-98 evaluating letrozole vs. letrozole followed by tamoxifen vs. tamoxifen followed by letrozole as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer. Cancer Res. 2009; 69 (Suppl). Abstract 76.
35. Pusztai L, Anderson K, Hess KR., Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. Clin Cancer Res. 2007; 13: 6080-6086. (Pubitemid 350075065)
36. Mandrekar SJ, Sargent DJ., Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol. 2009; 27: 4027-4034.
37. Freidlin B, McShane LM, Korn EL., Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst. 2010; 102: 152-160.
38. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25: 118-145. (Pubitemid 350003059)
39. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010; 134: e48-e72.
40. de Azambuja E, Cardoso F, de Castro G Jr, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007; 96: 1504-1513. (Pubitemid 46762956)
41. Mengel M, von Wasielewski R, Wiese B, Rudiger T, Muller-Hermelink HK, Kreipe H., Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol. 2002; 198: 292-299. (Pubitemid 35277379)
42. Dowsett M, Hanna WM, Kockx M, et al. Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod Pathol. 2007; 20: 584-591. (Pubitemid 46632000)
43. Wasielewski R, Hasselmann S, Ruschoff J, Fisseler-Eckhoff A, Kreipe H., Proficiency testing of immunohistochemical biomarker assays in breast cancer. Virchows Arch. 2008; 453: 537-543.
44. Mook S, Bonnefoi H, Pruneri G, et al. Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial. Eur J Cancer. 2009; 45: 1201-1208.
45. Simon RM, Paik S, Hayes DF., Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009; 101: 1445-1452.
46. Simon R., Advances in clinical trial designs for predictive biomarker discovery and validation. Cur Breast Cancer Rep. 2009, 1: 216-221.